June 20, 2024 - 🧬 [nGram] Today’s Oncology Scoop: Basilea Partners with Glioblastoma Foundation, iOnctura Secures EUR80M

  1. Basilea partners oncology drug candidate lisavanbulin with Glioblastoma Foundation
    • Basilea Pharmaceutica Ltd has entered into an asset purchase agreement with the Glioblastoma Foundation for lisavanbulin (BAL101553).
    • Lisavanbulin is a potential therapy for glioblastoma, the most common type of primary brain cancer.
    • The Glioblastoma Foundation will take over the development of lisavanbulin and continue the post-trial access program for patients.
    • Basilea will receive an undisclosed initial purchase price and a fixed double-digit percentage of future commercial proceeds.
    • Lisavanbulin has shown efficacy in phase 1 and 2 studies and has been granted Orphan Drug Designation by the FDA for malignant glioma.
    • The Glioblastoma Foundation plans to initiate clinical trials of lisavanbulin in the US.
    Read more

  2. Macomics and IOR announce macrophage scientific collaboration in prostate cancer drug development
    • Macomics Ltd and the Institute of Oncology Research (IOR) in Switzerland have entered a scientific collaboration.
    • The collaboration focuses on myeloid-derived suppressor cells in prostate cancer mouse model systems.
    • Macomics will work with Dr. Bianca Calì in Prof. Andrea Alimonti’s lab to explore new modes of action for macrophage-targeted therapies.
    • The collaboration aims to test novel drug candidates using advanced in vivo prostate cancer models developed by the Alimonti lab.
    • Macomics' ENIGMAC™ macrophage drug discovery platform will be utilized to discover novel targets and de-risk clinical translation.
    • The goal is to develop first-in-class medicines addressing diseases of high unmet medical need, particularly in prostate cancer.
    Read more

  3. Tubulis doses first patient in phase I/IIa trial investigating ADC candidate TUB-040 in ovarian cancer and lung adenocarcinoma
    • Tubulis has initiated its first Phase I/IIa trial (NAPISTAR 1-01, NCT06303505) for TUB-040.
    • The trial targets patients with platinum-resistant high-grade ovarian cancer (PROC) or relapsed/refractory adenocarcinoma non-small cell lung cancer (NSCLC).
    • TUB-040 is an antibody-drug conjugate (ADC) targeting NaPi2b, an antigen overexpressed in ovarian cancer and lung adenocarcinoma.
    • The study will be conducted in the US, UK, Spain, Belgium, and Germany.
    • Phase Ia will focus on dose escalation and safety, while Phase IIa will focus on dose optimization and preliminary efficacy.
    • The first patient has been dosed in the US following IND approval by the FDA.
    Read more

  4. iOnctura announces EUR80 million Series B financing to progress pipeline through Phase II trials
    • iOnctura closed an EUR80 million Series B financing led by Syncona Limited.
    • Funding will accelerate the development of roginolisib for uveal melanoma and other oncology indications.
    • Roginolisib, an allosteric modulator of PI3Kδ, has shown promising efficacy in Phase Ib trials for uveal melanoma.
    • Plans to commence trials in non-small cell lung cancer and primary myelofibrosis in late 2024.
    • Cambritaxestat, an autotaxin inhibitor, is in Phase Ib trials for metastatic pancreatic cancer.
    • Investors include the European Innovation Council Fund, M Ventures, Inkef Capital, VI Partners, Schroders Capital, and 3B Future Health Fund.
    Read more

  5. Combination targeted treatment produces lasting remissions in people with resistant aggressive B-cell lymphoma
    • NIH researchers developed a non-chemotherapy regimen called ViPOR for aggressive B-cell lymphoma.
    • The five-drug combination includes venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide.
    • In a clinical trial with 50 patients, 54% saw tumor reduction, and 38% achieved complete remission.
    • At two years, 36% of patients were alive, and 34% were disease-free, especially in specific DLBCL subtypes.
    • Side effects were generally mild to moderate, with only five patients discontinuing treatment early.
    • A larger phase 2 study is planned to confirm ViPOR's efficacy in non-GCB DLBCL and double-hit GCB DLBCL.
    Read more